Psychopharmacology of borderline personality disorder.
Psychopharmacology is widely used in the treatment of borderline personality disorder. However, support for this form of treatment has been largely based on case reports, case series, and open-label clinical trials. This evidence-based review examines the most recent randomized controlled trials of psychopharmacology in the treatment of borderline personality disorder, with a goal of highlighting the most promising pharmacotherapy for use in current clinical practice, as well as for future large-scale research testing. The results and limitations of the randomized controlled trial data are presented along with case vignettes illustrating the complexity of the disorder and the heterogeneity of its treatment. To date, there is at least some evidence-based support for the use of antipsychotics (conventional and atypical), monoamine oxidase inhibitors, serotonin reuptake inhibitors, and omega-3 fatty acids in the treatment of borderline personality disorder.
Raj
Y Pritham
YP
Department of Internal Medicine and Psychiatry, Duke University Medical Center, PO Box 3369 DUMC, Durham, NC 27710, USA. raj00002@mc.duke.edu
D000374:Aggression / Q000187:drug effects; D018692:Antimanic Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001883:Borderline Personality Disorder / Q000188:drug therapy* / Q000523:psychology; D003863:Depression / Q000188:drug therapy; D019317:Evidence-Based Medicine; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D016896:Treatment Outcome
D018692:Antimanic Agents; D014150:Antipsychotic Agents; D015525:Fatty Acids, Omega-3; D008996:Monoamine Oxidase Inhibitors; D011619:Psychotropic Drugs; D017367:Selective Serotonin Reuptake Inhibitors